Suppr超能文献

水溶性(氨基烷基)喜树碱类似物的合成:拓扑异构酶I的抑制作用及抗肿瘤活性。

Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

作者信息

Kingsbury W D, Boehm J C, Jakas D R, Holden K G, Hecht S M, Gallagher G, Caranfa M J, McCabe F L, Faucette L F, Johnson R K

机构信息

Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.

出版信息

J Med Chem. 1991 Jan;34(1):98-107. doi: 10.1021/jm00105a017.

Abstract

Water-soluble analogues of the antitumor alkaloid camptothecin (1) were prepared in which aminoalkyl groups were introduced into ring A or B. Most of the analogues were prepared by oxidation of camptothecin to 10-hydroxycamptothecin (2) followed by a Mannich reaction to give N-substituted 9-(aminomethyl)-10-hydroxycamptothecins (4-12) or by subsequent modification of Mannich product 4 (13, 15, 17, 19, 21). Others were obtained by modification of the hydroxyl group of 2 (25,26) or by total synthesis (35,42,43). These analogues, as well as some of their synthetic precursors, were evaluated for inhibition of topoisomerase I, cytotoxicity, and antitumor activity. Although there was not a quantitative correlation between these assays, compounds that inhibited topoisomerase I were also cytotoxic and demonstrated antitumor activity in vivo. Further evaluation of the most active water-soluble analogue led to the selection of 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent. In addition to its water solubility, ease of synthesis from natural camptothecin, and high potency, 4 demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.

摘要

制备了抗肿瘤生物碱喜树碱(1)的水溶性类似物,其中在A环或B环引入了氨烷基。大多数类似物是通过将喜树碱氧化为10-羟基喜树碱(2),然后进行曼尼希反应得到N-取代的9-(氨甲基)-10-羟基喜树碱(4-12),或者通过对曼尼希产物4进行后续修饰(13、15、17、19、21)来制备的。其他类似物则通过对2的羟基进行修饰(25、26)或通过全合成得到(35、42、43)。对这些类似物及其一些合成前体进行了拓扑异构酶I抑制、细胞毒性和抗肿瘤活性的评估。虽然这些测定之间没有定量相关性,但抑制拓扑异构酶I的化合物也具有细胞毒性,并在体内表现出抗肿瘤活性。对最具活性的水溶性类似物的进一步评估导致选择了9-[(二甲氨基)甲基]-10-羟基喜树碱(4,SK&F 104864)作为抗肿瘤药物进行开发。除了其水溶性、易于从天然喜树碱合成以及高效性外,4在临床前肿瘤模型中表现出广谱活性,目前正在癌症患者中进行I期临床试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验